University researcher and biotech company in vaccine collaboration
The University of Copenhagen has signed a commercial option agreement with a swizz-based biotech company concerning the development of new vaccines.
The biotech company has the option to market new vaccines based on a patented invention, while the research group responsible for the invention gains access to the company’s technology and facilities for the manufacturing of vaccines for humans and the carrying out of clinical trial phases.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
